Evidence map›Paper›PMID 42039852›Full record

ArticleInternational journal of nanomedicine2026

Synergistic Sono-Chemodynamic Therapy of Renal Cell Carcinoma Using HKUST-1@TiO

Sinian Zheng, Cong Li, Jiayu Chen, Kuo Zhang, Xiaobo Cui, Rubing Li, Zeming Weng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sinian ZhengDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, People's Republic of China.
Cong LiDepartment of Urology, Yuyao Hospital of Traditional Chinese Medicine, Ningbo, Zhejiang, People's Republic of China.
Jiayu ChenOperating Room, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, People's Republic of China.
Kuo ZhangDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, People's Republic of China.
Xiaobo CuiDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, People's Republic of China.
Rubing LiDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, People's Republic of China.
Zeming WengDepartment of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Renal cell carcinoma (RCC) is a common urinary malignancy with high postoperative recurrence, and current therapies are limited by toxicity or insufficient efficacy. Efficient sonodynamic therapy (SDT) strategies capable of generating reactive oxygen species (ROS) are urgently needed. This study aimed to develop a high-performance MOF-based heterojunction sonosensitizer to enhance ROS generation and achieve effective anti-tumor activity. Methods: We synthesized HKUST-1@TiO Results: HKUST-1@TiO Conclusion: HKUST-1@TiO

Indexed as

Carcinoma, Renal CellKidney NeoplasmsTitaniumUltrasonic TherapyAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalHumansMiceMice, Inbred BALB CMice, NudeReactive Oxygen SpeciesXenograft Model Antitumor AssaysReactive Oxygen SpeciesTitaniumtitanium dioxideheterojunctionmetal-organic frameworksreactive oxygen speciesrenal cell carcinomasonodynamic therapytitanium dioxide

Identifiers

PMID42039852
PMCPMC13110025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.